Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Deborah Collyar: What's In It for Patients?

Welcome and Introduction to Vi3C

Advertisement

Advertisement




Oct
22
Today In Oncology
Adjuvant Pembrolizumab in Merkel Cell Carcinoma
Final FLAURA2 Analysis Confirms First-Line Benefit of Osimertinib-Chemotherapy in EGFR-Positive NSCLC
Impact of HER2-Receptor Status in mCRC Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs
Localized PI3K-Altered Colorectal Cancer Does Low-Dose Aspirin Reduce the Risk of Recurrence
ESMO Publishes Guidance on Large Language Model Use for Oncology Practice
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo